L-BLP25 vaccine plus letrozole for breast cancer: Is translation possible?

Michael DeGregorio, Gregory T. Wurz, Audrey Gutierrez, Michael Wolf

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

We have recently reported immunomodulatory effects for tamoxifen and letrozole on the L-BLP25 (Stimuvax@®)-induced immune response in a MUC1-expressing breast cancer mouse model. While neither tamoxifen nor letrozole appeared to interfere with the Th1-polarized cytokine response induced by L-BLP25, only letrozole increased the survival advantage of L-BLP25.

Original languageEnglish (US)
Pages (from-to)1422-1424
Number of pages3
JournalOncoImmunology
Volume1
Issue number8
DOIs
StatePublished - 2012

Keywords

  • Breast cancer
  • L-BLP25
  • Letrozole
  • MMT model
  • Tamoxifen

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Fingerprint Dive into the research topics of 'L-BLP25 vaccine plus letrozole for breast cancer: Is translation possible?'. Together they form a unique fingerprint.

  • Cite this

    DeGregorio, M., Wurz, G. T., Gutierrez, A., & Wolf, M. (2012). L-BLP25 vaccine plus letrozole for breast cancer: Is translation possible? OncoImmunology, 1(8), 1422-1424. https://doi.org/10.4161/onci.21129